Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial parkinson's disease α-synuclein A53T mutation

Neurochemical Research

Volumn 35, Issue 1, 2010, Pages 130-142

  Ma, Lei ^a   Cao, Tracy T ^a   Kandpal, Geeta ^a   Warren, Lee ^a   Fred Hess, J ^a   Seabrook, Guy R ^a   Ray, William J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

6 OHDA; Alpha synuclein; Antioxidants; Microarray analysis; MPP+; Parkinson's disease

Indexed keywords

ADENOSINE; ALPHA SYNUCLEIN; ANTIOXIDANT; DNA; NORPHENAZONE; OXIDOPAMINE; PROTEIN P53; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT ACTIVITY; ARTICLE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MICROARRAY; FAMILIAL DISEASE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; WILD TYPE;

ALPHA-SYNUCLEIN; ANTIOXIDANTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; GENOME; HUMANS; MUTATION; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE;

EID: 76849117517     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-009-0038-1     Document Type: Article

References (61)

1. A Barzilai E Melamed 2003 Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease Trends Mol Med 9 126 132 10.1016/S1471-4914(03)00020-0 1:CAS:528:DC%2BD3sXit1yqurk%3D 12657434 (Pubitemid 36433894)
2. V Bogaerts J Theuns C van Broeckhoven 2008 Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav 7 129 151 10.1111/j.1601-183X.2007.00342.x 1:CAS:528:DC%2BD1cXks1Sqtrg%3D 17680806 (Pubitemid 351342198)
3. R Kruger W Kuhn T Muller D Woitalla M Graeber S Kosel H Przuntek JT Epplen L Schols O Riess 1998 Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 106 108 10.1038/ng0298-106 1:CAS:528:DyaK1cXosFCntA%3D%3D 9462735
4. JJ Zarranz J Alegre JC Gomez-Esteban E Lezcano R Ros I Ampuero L Vidal J Hoenicka O Rodriguez B Atares, et al. 2004 The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 164 173 10.1002/ana.10795 1:CAS:528:DC%2BD2cXhs1Sgtb0%3D 14755719 (Pubitemid 38166992)
5. MH Polymeropoulos C Lavedan E Leroy SE Ide A Dehejia A Dutra B Pike H Root J Rubenstein R Boyer, et al. 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 2045 2047 10.1126/science.276.5321.2045 1:CAS:528:DyaK2sXkt1altr4%3D 9197268 (Pubitemid 27443610)
6. BI Giasson K Uryu JQ Trojanowski VM Lee 1999 Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro J Biol Chem 274 7619 7622 10.1074/jbc.274.12.7619 1:CAS:528: DyaK1MXitFSktrw%3D 10075647 (Pubitemid 29144220)
7. KA Conway SJ Lee JC Rochet TT Ding JD Harper RE Williamson PT Lansbury Jr 2000 Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants Ann N Y Acad Sci 920 42 45 1:CAS:528:DC%2BD3MXotlWqsg%3D%3D 11193175
8. BI Giasson MS Forman M Higuchi LI Golbe CL Graves PT Kotzbauer JQ Trojanowski VM Lee 2003 Initiation and synergistic fibrillization of tau and alpha-synuclein Science 300 636 640 10.1126/science.1082324 1:CAS:528: DC%2BD3sXjtVymu70%3D 12714745 (Pubitemid 36520587)
9. MJ Volles PT Lansbury Jr 2002 Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism Biochemistry 41 4595 4602 10.1021/bi0121353 1:CAS:528:DC%2BD38XhvVeqt70%3D 11926821 (Pubitemid 34275660)
10. J Liang C Clark-Dixon S Wang TR Flower T Williams-Hart R Zweig LC Robinson K Tatchell SN Witt 2008 Novel suppressors of alpha-synuclein toxicity identified using yeast Hum Mol Genet 17 3784 3795 10.1093/hmg/ddn276 1:CAS:528:DC%2BD1cXhtlGisrfK 18772193
11. SJ Tabrizi M Orth JM Wilkinson JW Taanman TT Warner JM Cooper AH Schapira 2000 Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity Hum Mol Genet 9 2683 2689 10.1093/hmg/9.18.2683 1:CAS:528:DC%2BD3cXosVKktbw%3D 11063727
12. LJ Hsu Y Sagara A Arroyo E Rockenstein A Sisk M Mallory J Wong T Takenouchi M Hashimoto E Masliah 2000 Alpha-synuclein promotes mitochondrial deficit and oxidative stress Am J Pathol 157 401 410 1:CAS:528: DC%2BD3cXlvFyru7k%3D 10934145
13. A Hunya I Foldi V Szegedi K Soos M Zarandi A Szabo D Zadori B Penke ZL Datki 2008 Differences between normal and alpha-synuclein overexpressing SH-SY5Y neuroblastoma cells after Abeta(1-42) and NAC treatment Brain Res Bull 75 648 654 10.1016/j.brainresbull.2007.10.035 1:CAS:528:DC%2BD1cXjs1Kkt7k%3D 18355641
14. S Kanda JF Bishop MA Eglitis Y Yang MM Mouradian 2000 Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation Neuroscience 97 279 284 10.1016/S0306-4522(00)00077-4 1:CAS:528:DC%2BD3cXivVCqsrc%3D 10799759 (Pubitemid 30224765)
15. S Batelli D Albani R Rametta L Polito F Prato M Pesaresi A Negro G Forloni 2008 DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70 PLoS ONE 3 e1884 10.1371/journal.pone.0001884 18382667 (Pubitemid 351943824)
16. WH Yu Y Matsuoka I Sziraki A Hashim J Lafrancois H Sershen KE Duff 2008 Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein Neurochem Res 33 902 911 10.1007/s11064-007-9533-4 1:CAS:528:DC%2BD1cXjsFGit74%3D 17999181
17. M Nieto FJ Gil-Bea E Dalfo M Cuadrado F Cabodevilla B Sanchez S Catena T Sesma E Ribe I Ferrer, et al. 2006 Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice Neurobiol Aging 27 848 856 10.1016/j.neurobiolaging.2005.04.010 1:CAS:528:DC%2BD28XksVajtrs%3D 16006012
18. S Rathke-Hartlieb PJ Kahle M Neumann L Ozmen S Haid M Okochi C Haass JB Schulz 2001 Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice J Neurochem 77 1181 1184 10.1046/j.1471-4159.2001.00366.x 1:CAS:528:DC%2BD3MXktVWitLs%3D 11359883 (Pubitemid 32467072)
19. A Samii JG Nutt BR Ransom 2004 Parkinson's disease Lancet 363 1783 1793 10.1016/S0140-6736(04)16305-8 1:CAS:528:DC%2BD2cXksVanu7k%3D 15172778 (Pubitemid 38698383)
20. DT Dexter AE Holley WD Flitter TF Slater FR Wells SE Daniel AJ Lees P Jenner CD Marsden 1994 Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study Mov Disord 9 92 97 10.1002/mds.870090115 1:STN:280:DyaK2c7oslOruw%3D%3D 8139611 (Pubitemid 24022621)
21. ZI Alam A Jenner SE Daniel AJ Lees N Cairns CD Marsden P Jenner B Halliwell 1997 Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra J Neurochem 69 1196 1203 1:CAS:528:DyaK2sXls1Chtbs%3D 9282943
22. DT Dexter CJ Carter FR Wells F Javoy-Agid Y Agid A Lees P Jenner CD Marsden 1989 Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 381 389 10.1111/j.1471-4159.1989.tb09133.x 1:CAS:528:DyaL1MXhtFalsrc%3D 2911023 (Pubitemid 19037600)
23. BI Giasson H Ischiropoulos VM Lee JQ Trojanowski 2002 The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases Free Radic Biol Med 32 1264 1275 10.1016/S0891-5849(02) 00804-3 1:CAS:528:DC%2BD38XktFyhsb4%3D 12057764 (Pubitemid 34607630)
24. PF Good A Hsu P Werner DP Perl CW Olanow 1998 Protein nitration in Parkinson's disease J Neuropathol Exp Neurol 57 338 342 10.1097/00005072- 199804000-00006 1:STN:280:DyaK1c3mtVymtg%3D%3D 9600227
25. R Betarbet TB Sherer G MacKenzie M Garcia-Osuna AV Panov JT Greenamyre 2000 Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 1301 1306 10.1038/81834 1:CAS:528:DC%2BD3cXosVGgsbg%3D 11100151 (Pubitemid 30951645)
26. BR Bloem I Irwin OJ Buruma J Haan RA Roos JW Tetrud JW Langston 1990 The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease J Neurol Sci 97 273 293 10.1016/0022-510X(90)90225-C 1:CAS:528:DyaK3MXlsFSkuw%3D%3D 2205710 (Pubitemid 20231246)
27. H Sauer WH Oertel 1994 Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine a combined retrograde tracing and immunocytochemical study in the rat Neuroscience 59 401 415 10.1016/0306-4522(94)90605-X 1:CAS:528:DyaK2cXisVWktL4%3D 7516500 (Pubitemid 24098798)
28. CW Shults D Oakes K Kieburtz MF Beal R Haas S Plumb JL Juncos J Nutt I Shoulson J Carter, et al. 2002 Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline Arch Neurol 59 1541 1550 10.1001/archneur.59.10.1541 12374491
29. Y Levites O Weinreb G Maor MB Youdim S Mandel 2001 Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration J Neurochem 78 1073 1082 10.1046/j.1471-4159.2001.00490.x 1:CAS:528:DC%2BD3MXms12rs7w%3D 11553681 (Pubitemid 32823156)
30. CF Jin SR Shen Sr BL Zhao 2001 Different effects of five catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells J Agric Food Chem 49 6033 6038 10.1021/jf010903r 1:CAS:528:DC%2BD3MXosFCqt78%3D 11743804 (Pubitemid 34062574)
31. L Wang S Xu X Xu P Chan 2009 (-)-Epigallocatechin-3-gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through STAT3 activation J Alzheimers Dis 17 295 304 1:CAS:528:DC%2BD1MXmvVOiurs%3D 19221405
32. WJ Yuan T Yasuhara T Shingo K Muraoka T Agari M Kameda T Uozumi N Tajiri T Morimoto M Jing, et al. 2008 Neuroprotective effects of edaravone- administration on 6-OHDA-treated dopaminergic neurons BMC Neurosci 9 75 10.1186/1471-2202-9-75 18671880
33. H Chen S Wang JH Ding G Hu 2008 Edaravone protects against MPP+-induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway J Neurochem 106 2345 2352 10.1111/j.1471-4159.2008.05573.x 1:CAS:528:DC%2BD1cXhtFOit7nN 18643790
34. TR Hughes M Mao AR Jones J Burchard MJ Marton KW Shannon SM Lefkowitz M Ziman JM Schelter MR Meyer, et al. 2001 Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer Nat Biotechnol 19 342 347 10.1038/86730 1:CAS:528:DC%2BD3MXis1Smsb0%3D 11283592 (Pubitemid 32275343)
35. L Weng H Dai Y Zhan Y He SB Stepaniants DE Bassett 2006 Rosetta error model for gene expression analysis Bioinformatics 22 1111 1121 10.1093/bioinformatics/btl045 1:CAS:528:DC%2BD28XjslKrsbg%3D 16522673
36. E Carrasco D Casper P Werner 2005 Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity J Neurosci Res 81 121 131 10.1002/jnr.20541 1:CAS:528:DC%2BD2MXlvFCks7g%3D 15931668 (Pubitemid 41139117)
37. SH Park WS Choi SY Yoon YS Ahn YJ Oh 2004 Activation of NF-kappaB is involved in 6-hydroxydopamine-but not MPP+-induced dopaminergic neuronal cell death: its potential role as a survival determinant Biochem Biophys Res Commun 322 727 733 10.1016/j.bbrc.2004.07.193 1:CAS:528:DC%2BD2cXntFeqs7s%3D 15336524 (Pubitemid 39164413)
38. C Cleren B Naudin J Costentin 2003 Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons Brain Res 989 187 195 10.1016/S0006-8993(03)03333-X 1:CAS:528:DC%2BD3sXnvFSht7s%3D 14556940 (Pubitemid 37211422)
39. KL O'Malley J Liu J Lotharius W Holtz 2003 Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons Neurobiol Dis 14 43 51 10.1016/S0969-9961(03)00013-5 13678665 (Pubitemid 37103178)
40. BS Han JS Noh BJ Gwag YJ Oh 2003 A distinct death mechanism is induced by 1-methyl-4-phenylpyridinium or by 6-hydroxydopamine in cultured rat cortical neurons: degradation and dephosphorylation of tau Neurosci Lett 341 99 102 10.1016/S0304-3940(03)00173-3 1:CAS:528:DC%2BD3sXislensrY%3D 12686375 (Pubitemid 36398479)
41. WS Choi SY Yoon TH Oh EJ Choi KL O'Malley YJ Oh 1999 Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK J Neurosci Res 57 86 94 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E 1:CAS:528:DyaK1MXktFCht7s%3D 10397638 (Pubitemid 29293582)
42. J Lotharius LL Dugan KL O'Malley 1999 Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons J Neurosci 19 1284 1293 1:CAS:528:DyaK1MXhtFOhsrw%3D 9952406
43. WS Wu S Heinrichs D Xu SP Garrison GP Zambetti JM Adams AT Look 2005 Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma Cell 123 641 653 10.1016/j.cell.2005.09.029 1:CAS:528:DC%2BD2MXht1yktrjO 16286009 (Pubitemid 41613746)
44. E Sanz A Quintana V Battaglia A Toninello J Hidalgo S Ambrosio M Valoti JL Marco KF Tipton M Unzeta 2008 Anti-apoptotic effect of Mao-B inhibitor PF9601 N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP(+)-treated SH-SY5Y human dopaminergic cells J Neurochem 105 2404 2407 10.1111/j.1471-4159.2008.05326.x 1:CAS:528: DC%2BD1cXnvVWiurg%3D (Pubitemid 351782267)
45. W Duan X Zhu B Ladenheim QS Yu Z Guo J Oyler RG Cutler JL Cadet NH Greig MP Mattson 2002 p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism Ann Neurol 52 597 606 10.1002/ana.10350 1:CAS:528:DC%2BD38XovFKkt74%3D 12402257 (Pubitemid 35246863)
46. TT Cao L Ma G Kandpal L Warren JF Hess GR Seabrook 2005 Increased nuclear factor-erythroid 2 p45-related factor 2 activity protects SH-SY5Y cells against oxidative damage J Neurochem 95 406 417 10.1111/j.1471-4159.2005.03377.x 1:CAS:528:DC%2BD2MXhtFegu7vL 16092930 (Pubitemid 41457509)
47. L Westergard HM Christensen DA Harris 2007 The cellular prion protein (PrP(C)): its physiological function and role in disease Biochim Biophys Acta 1772 629 644 1:CAS:528:DC%2BD2sXmtlWjurs%3D 17451912
48. MM Babu NM Luscombe L Aravind M Gerstein SA Teichmann 2004 Structure and evolution of transcriptional regulatory networks Curr Opin Struct Biol 14 283 291 10.1016/j.sbi.2004.05.004 1:CAS:528:DC%2BD2cXkvV2nsbw%3D 15193307 (Pubitemid 38749055)
49. M Shimojo LB Hersh 2006 Characterization of the REST/NRSF-interacting LIM domain protein (RILP): localization and interaction with REST/NRSF J Neurochem 96 1130 1138 10.1111/j.1471-4159.2005.03608.x 1:CAS:528:DC%2BD28XivFWjs70%3D 16417580
50. VV Lunyak MG Rosenfeld 2005 No rest for REST: REST/NRSF regulation of neurogenesis Cell 121 499 501 10.1016/j.cell.2005.05.003 1:CAS:528: DC%2BD2MXkslels70%3D 15907461 (Pubitemid 40720001)
51. E Andersson JB Jensen M Parmar F Guillemot A Bjorklund 2006 Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2 Development 133 507 516 10.1242/dev.02224 1:CAS:528: DC%2BD28Xit1KmtL8%3D 16396906 (Pubitemid 43273836)
52. S Pandey E Wang 1995 Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling events of early cell-cycle traverse J Cell Biochem 58 135 150 10.1002/jcb.240580203 1:CAS:528:DyaK2MXmtlOntrk%3D 7673322
53. HC Hsu T Zhou JD Mountz 2004 Nur77 family of nuclear hormone receptors Curr Drug Targets Inflamm Allergy 3 413 423 10.2174/1568010042634523 1:CAS:528:DC%2BD2cXhtVWitbjE 15584889 (Pubitemid 39534776)
54. JE Chipuk L Bouchier-Hayes T Kuwana DD Newmeyer DR Green 2005 PUMA couples the nuclear and cytoplasmic proapoptotic function of p53 Science 309 1732 1735 10.1126/science.1114297 1:CAS:528:DC%2BD2MXpvFCis7s%3D 16151013 (Pubitemid 41285944)
55. R Venugopal AK Jaiswal 1996 Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene Proc Natl Acad Sci USA 93 14960 14965 10.1073/pnas.93.25.14960 1:CAS:528:DyaK28XnsVOrsLY%3D 8962164 (Pubitemid 26419078)
56. R Venugopal AK Jaiswal 1998 Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes Oncogene 17 3145 3156 10.1038/sj.onc.1202237 1:CAS:528:DyaK1MXlsFajtQ%3D%3D 9872330
57. P Moi K Chan I Asunis A Cao YW Kan 1994 Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region Proc Natl Acad Sci USA 91 9926 9930 10.1073/pnas.91.21.9926 1:CAS:528: DyaK2MXht1Cmsbc%3D 7937919 (Pubitemid 24311921)
58. T Nguyen PJ Sherratt CB Pickett 2003 Regulatory mechanisms controlling gene expression mediated by the antioxidant response element Annu Rev Pharmacol Toxicol 43 233 260 10.1146/annurev.pharmtox.43.100901.140229 1:CAS:528:DC%2BD3sXitFWqsbY%3D 12359864 (Pubitemid 37372641)
59. D Acosta-Alvear Y Zhou A Blais M Tsikitis NH Lents C Arias CJ Lennon Y Kluger BD Dynlacht 2007 XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks Mol Cell 27 53 66 10.1016/j.molcel.2007.06. 011 1:CAS:528:DC%2BD2sXot1els7s%3D 17612490 (Pubitemid 46991391)
60. WA Holtz KL O'Malley 2003 Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons J Biol Chem 278 19367 19377 10.1074/jbc.M211821200 1:CAS:528:DC%2BD3sXjvVSktrk%3D 12598533 (Pubitemid 36799332)
61. JJ Hoozemans ES van Haastert P Eikelenboom RA de Vos JM Rozemuller W Scheper 2007 Activation of the unfolded protein response in Parkinson's disease Biochem Biophys Res Commun 354 707 711 10.1016/j.bbrc.2007.01.043 1:CAS:528:DC%2BD2sXhtlOgu74%3D 17254549 (Pubitemid 46186242)